A new cell-permeable peptide allows successful allogeneic islet transplantation in mice

Nature Medicine

Volumn 10, Issue 3, 2004, Pages 305-309

  Noguchi, Hirofumi ^a,b   Matsushita, Masayuki ^a   Okitsu, Teru ^a,b   Moriwaki, Akiyoshi ^a   Tomizawa, Kazuhito ^a   Kang, Sunghyun ^c   Li, Sheng Tian ^a   Kobayashi, Naoya ^a   Matsumoto, Shinichi ^b   Tanaka, Koich ^b   Tanaka, Noriaki ^a   Matsui, Hideki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; POLYARGININE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; DNA BINDING PROTEIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; NUCLEAR PROTEIN; OLIGOPEPTIDE; PEPTIDE; TRANSCRIPTION FACTOR; VIVIT PEPTIDE;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REPORTER GENE; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GRAFT SURVIVAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PANCREAS ISLET; PERMEABILITY; SECRETION; T LYMPHOCYTE;

ANIMALIA;

ANIMALS; DNA-BINDING PROTEINS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INTERLEUKIN-2; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; OLIGOPEPTIDES; PEPTIDES; PERMEABILITY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TACROLIMUS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2342526607     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm994     Document Type: Article

References (21)

1. Lindgren, M., Hällbrink, M., Prochiantz, A & Langel, O. Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99-103 (2000).
2. Schwarze, S.R. & Dowdy, S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21, 45-48 (2000).
3. Chellaiah, M.A. et al. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J. Biol. Chem. 275, 11993-20002 (2000).
4. Dostmann, W.R. et al. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase 1α inhibit NO-induced cerebral dilation. Proc. Natl. Acad. Sci. USA 97, 14772-14777 (2000).
5. Gallouzi, I.E. & Steitz, J.A. Delineation of mRNA export pathways by the use of cell-permeable peptides, Science 294, 1895-1901 (2001).
6. Schwarze, S.R., Ho, A., Vocero-Akbani, A. & Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999).
7. Rao, A., Luo, C. & Hogan, P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707-747 (1997).
8. 2+, calcineurin, and NF-AT. Cell 96, 611-6114 (1999).
9. Sigal, N.H. etal. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Exp. Med. 173. 619-628 (1991).
10. Platz, K.P. et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58, 170-178 (1994).
11. Pascual, M. et al. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol. Today 19, 514-519 (1998).
12. Holo, M. et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397, 530-534 (1999).
13. Aramburu, J. et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285, 2129-2133 (1999).
14. Wender, P.A. et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97, 13003-13008 (2000).
15. Futaki, S. et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836-5840 (2001).
16. Matsushita, M. et al. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J. Neurosci. 21, 6000-6007 (2001).
17. Matsui, H., Tomizawa, K., Lu, Y.-F. & Matsushita, M. Protein therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr. Protein Pept Sci. 4, 151-157 (2003).
18. Odocha, O. et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK506 immunosuppression. Transplant. Proc. 25, 2433-2434 (1993).
19. Okitsu, T. et al. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am. J. Transplantation 1, 138-145 (2001).
20. Redmon, J.B. et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J. Clin. Invest. 98, 2786-2793 (1996).
21. Todt, J. et al. Repeated intratracheal challenge with particulate antigen modulates murine lung cytokines. J. Immunol. 164, 4037-4047 (2000).